Ozempic Gastroparesis Settlement: Claim Valuation Factors Overview

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Exposure-Specific Risk

For decades, public health communication has centered on general wellness and the broad dissemination of scientific information. This legacy framework emphasized preventive care, lifestyle management, and the responsible use of medications to improve population health. Within this context, the public has been educated about common side effects and the importance of monitoring treatment responses. As medical knowledge advances, however, the focus has necessarily shifted from general health maintenance to more specific exposure-related considerations. In the realm of mass production, particularly in pharmaceutical manufacturing and distribution, workers and consumers alike may encounter concentrated forms of therapeutic compounds. This transition from a general health paradigm to one concerned with occupational and environmental exposure requires careful attention. The same medications that offer therapeutic benefits in controlled doses can present distinct risks when exposure occurs outside clinical supervision. Understanding this pivot is essential for evaluating how historical health information frameworks must adapt to address emerging concerns about unintended exposure in production and supply chain contexts.

The Medical Link: Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Its pharmacological action slows gastric emptying, a mechanism that can become pathologically exaggerated, leading to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. Clinical presentation of gastroparesis includes early satiety, postprandial fullness, nausea, vomiting, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy showing delayed emptying after a standardized meal. Evidence from FDA adverse event reports (FAERS) indicates that "IMPAIRED GASTRIC EMPTYING" is among the most frequently reported adverse events associated with Ozempic, with 2,693 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). This signal is supported by clinical trial data showing that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo: in placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was also higher: 3.1% for Ozempic 0.5 mg and 3.8% for Ozempic 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data collectively indicate a dose-dependent increase in gastrointestinal adverse effects, with impaired gastric emptying being a recognized consequence of GLP-1 receptor agonism.

Mechanistic Pathway and Risk Anchors

The mechanistic pathway linking Ozempic to gastroparesis involves delayed gastric emptying as a direct pharmacodynamic effect. GLP-1 receptors are expressed on gastric smooth muscle and enteric neurons; activation inhibits antral contractions and stimulates pyloric tone, slowing gastric emptying. In susceptible individuals, this effect may become persistent and symptomatic, meeting diagnostic criteria for gastroparesis. The timeline between exposure and documented harm is variable, but FAERS data show that impaired gastric emptying is reported during treatment, often within weeks to months of initiation, particularly during dose escalation when gastrointestinal adverse reactions are most common (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Risk anchors for settlement considerations include the adequacy of warnings. The Ozempic label lists gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct adverse event. The label states that "the majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not mention gastroparesis or impaired gastric emptying as a potential serious adverse reaction. This gap in labeling may be relevant in litigation, as patients and prescribers may not have been adequately informed of the risk of developing a chronic motility disorder.

Claim Valuation Factors for Affected Patients

Settlement-related considerations for affected patients include the severity and duration of gastroparesis, which can be debilitating and require long-term management including dietary modifications, prokinetic agents, and in severe cases, gastric electrical stimulation or feeding tubes. The economic impact includes medical costs, lost wages, and reduced quality of life. Claim valuation factors typically include the strength of the causal link (supported by FAERS data and pharmacological plausibility), the severity of harm, the adequacy of warnings, and the timeline between exposure and harm. Patients who developed gastroparesis after Ozempic use and who can demonstrate that their symptoms were not pre-existing may have stronger claims. The timeline between exposure and documented harm is critical. FAERS data show that impaired gastric emptying is reported during treatment, often within the first few months, and may persist after discontinuation. The dose-response relationship observed in clinical trials (higher rates of gastrointestinal adverse reactions at higher doses) supports a causal relationship. Patients who experienced onset of gastroparesis symptoms during dose escalation or shortly after starting Ozempic, and who had no prior history of gastric motility disorders, may have stronger evidence of causation. In summary, the evidence from clinical trials and FAERS reports indicates that Ozempic is associated with impaired gastric emptying, which can manifest as gastroparesis. The pharmacological mechanism is well-established, and the risk appears dose-dependent. Inadequate labeling regarding this specific adverse event may be a factor in settlement negotiations. Affected patients should document their symptom onset, treatment timeline, and any prior gastrointestinal history to support their claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism. In some individuals, this effect becomes exaggerated and persistent, leading to gastroparesis—a condition of delayed gastric emptying without obstruction. Clinical trial data show dose-dependent increases in gastrointestinal adverse reactions, and FAERS reports list impaired gastric emptying as a frequent adverse event (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC).

What factors affect the value of an Ozempic gastroparesis claim?

Key factors include the strength of the causal link (supported by FAERS data and pharmacological plausibility), severity and duration of gastroparesis, economic impact (medical costs, lost wages), adequacy of warnings on the label, and the timeline between Ozempic exposure and symptom onset. Patients without pre-existing gastric issues and with onset during dose escalation may have stronger claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.